VIGIL NEUROSCIENCE INC. - COMMON STOCK

Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927

17 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience to Present at Cantor Global Healthcare Conference

16 سبتمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience to Present at Upcoming September Investor Conferences

29 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update

13 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics

01 أغسطس 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)  

30 يوليو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease

24 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference

18 يوليو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP

18 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi

27 يونيو 2024 02:00:03 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience to Present in Upcoming June Investor Conferences

30 مايو 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference

08 مايو 2024 07:40:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update

07 مايو 2024 16:05:01 بحسب Nasdaq GlobeNewswire

Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting

17 أبريل 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

26 مارس 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer

20 مارس 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting

13 مارس 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days

12 مارس 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024

06 مارس 2024 16:25:47 بحسب Nasdaq GlobeNewswire

Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024

29 فبراير 2024 16:05:00 بحسب Nasdaq GlobeNewswire